Rewriting the Economics of Genomics Through Minos (Bittensor Subnet 107)
Genomic medicine has already changed oncology, what it has not changed is access. Today, sequencing a patient’s DNA and identifying clinically meaningful mutations is technically possible, scientifically validated, and commercially available. Yet it remains slow, expensive, and centralized. Turnaround times can stretch for weeks, costs can run into the thousands (if not millions), and the…